Andrew Reardon, CLO & Secretary at Ligand Pharmaceuticals, sold LGND on Jul 1, 2026
Data as of Oct 16
- Traded
- Jul 1, 2026
- Disclosed
- Jul 6, 2026
- Filed
- 5 days after the trade · late
Form 4s are due within two business days.
Official filing (SEC Form 4) ↗
The price around the disclosure
LGND since disclosure
−7.8%
after the sale
Similar stocks (XLV) since disclosure
+9.1%
XLV — its sector index fund
Change in closing price from Jul 6, 2026 (the first trading day on or after disclosure) to Oct 16, 2026. Dividends excluded. Not a return anyone earned.
Our take
None of our tested rules fired on this trade.
Other trades in the same filing
- ▼ SELLAndrew Reardon CLO & SecretaryLGND Ligand Pharmaceuticals Inc$32.3Kdisclosed Jul 6 · filed 5 days after the trade · late
- ▼ SELLAndrew Reardon CLO & SecretaryLGND Ligand Pharmaceuticals Inc$190Kdisclosed Jul 6 · filed 5 days after the trade · late
- ▼ SELLAndrew Reardon CLO & SecretaryLGND Ligand Pharmaceuticals Inc$31.5Kdisclosed Jul 6 · filed 5 days after the trade · late
- ▼ SELLAndrew Reardon CLO & SecretaryLGND Ligand Pharmaceuticals Inc$338Kdisclosed Jul 6 · filed 5 days after the trade · late
- ▼ SELLAndrew Reardon CLO & SecretaryLGND Ligand Pharmaceuticals Inc$122Kdisclosed Jul 6 · filed 5 days after the trade · late
- ▼ SELLAndrew Reardon CLO & SecretaryLGND Ligand Pharmaceuticals Inc$284Kdisclosed Jul 6 · filed 5 days after the trade · late
- ▼ SELLAndrew Reardon CLO & SecretaryLGND Ligand Pharmaceuticals Inc$349Kdisclosed Jul 6 · filed 5 days after the trade · late